title: IL-17 in human asthma.
abstract: Asthma is perceived as a heterogeneous disease with several clinical phenotypes and triggering factors. In general, cytokines from T-helper 2 cells are believed to be critical contributors of asthma. In recent years, IL-17, another T-helper lymphocyte-associated cytokine, has been put forward as another potentially important mediator of asthma. Currently, several drugs that target IL-17 signaling are being tested in clinical trials. With the aim to find whether there are any specific features of this heterogeneous disease that potentially could be relieved by the use of IL-17-targeting drugs, this review scrutinizes the evidence for an involvement of IL-17 in human asthma.
authors.affiliation: William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. e.c.silverpil@qmul.ac.uk
authors.forename: Elin
authors.initials: E
authors.lastname: Silverpil
authors.forename: Anders
authors.initials: A
authors.lastname: Lindén
mesh_terms: D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction; D058504:Th17 Cells / Q000276:immunology*
chemical_list: D020381:Interleukin-17